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Episodic ataxia (EA) syndromes are heritable diseases characterized by dramatic episodes
of imbalance and incoordination. EA type 2 (EA2), the most common and the best char-
acterized subtype, is caused by mostly nonsense, splice site, small indel, and sometimes
missense mutations in CACNA1A. Direct sequencing of CACNA1A fails to identify muta-
tions in some patients with EA2-like features, possibly due to incomplete interrogation
of CACNA1A or defects in other EA genes not yet defined. Previous reports described
genomic deletions between 4 and 40 kb in EA2. In 47 subjects with EA (26 with EA2-like
features) who tested negative for mutations in the known EA genes, we used multi-
plex ligation-dependent probe amplification to analyze CACNA1A for exonic copy number
variations. Breakpointswere further defined by long-range PCR.We identified distinctmulti-
exonic deletions in three probands with classic EA2-like features: episodes of prolonged
vertigo and ataxia triggered by stress and fatigue, interictal nystagmus, with onset dur-
ing infancy or early childhood. The breakpoints in all three probands are located in Alu
sequences, indicating errors in homologous recombination of Alu sequences as the under-
lyingmechanism.The smallest deletion spanned exons 39 and 40,while the largest deletion
spanned 200 kb, missing all but the first three exons. One deletion involving exons 39
through 47 arose spontaneously. The search for mutations in CACNA1A appears most
fruitful in EA patients with interictal nystagmus and onset early in life. The finding of large
heterozygous deletions suggests haploinsufficiency as a possible pathomechanism of EA2.
Keywords: episodic ataxia, EA2, genomic rearrangement, CACNA1A, mutation
INTRODUCTION
Episodic ataxia (EA) syndromes are heritable diseases character-
ized by dramatic episodes of imbalance and incoordination (Jen
et al., 2007). EA is clinically and genetically heterogeneous, with at
least seven subtypes described to date. EA type 2 (EA2), the most
common and the best characterized subtype, is defined by muta-
tions in CACNA1A, which encodes Cav2.1, the main subunit of
the P/Q type voltage-gated calcium channel (Ophoff et al., 1996).
Clinically,EA2 is characterized by recurrent vertigo and ataxia last-
ing hours commonly triggered by physical exertion or emotional
stress. EA2 typically presents early in life and is variably associated
with interictal nystagmus and progressive ataxia. Direct sequenc-
ing has identified point or small indel mutations that span the
entire gene, most of which are nonsense, splice site, or frameshift
mutations predicted to lead to nonsense-mediated mRNA decay
or truncated proteins to cause loss of channel function (Jen et al.,
2007).
There are still many patients who exhibit EA2-like clinical
features in whom no mutation has been identified; this lack of
success in finding mutations has often been attributed to incom-
plete interrogation of theCACNA1A gene or genetic heterogeneity
(Denier et al., 1999; Jen et al., 2004; Graves and Hanna, 2008;
Mantuano et al., 2010). The use of alternative techniques led to
recent reports of multi-exonic deletions of 4–40 kb in EA2 (Riant
et al., 2008, 2010; Labrum et al., 2009). The exact breakpoints
were ascertained in five individuals (Riant et al., 2008, 2010);
all involved Alu elements, which are short interspersed elements
around300bases in length that comprise themost abundant repet-
itive sequences, an estimated 10%, in the human genome and are
known to mediate recombination (Cordaux and Batzer, 2009). All
index patients harboring large deletions presented before age 30
(Riant et al., 2008, 2010; Labrum et al., 2009). Similarly, the yield
for mutation screening by sequencing in those with late-onset
EA is low, with genetic confirmation of EA2 in only two patients
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with onset after age 50 (Imbrici et al., 2005; Cuenca-Leon et al.,
2009).
In this study, we searched for genomic rearrangement in
CACNA1A in patients with onset of EA before age 30 in whom
no mutations in EA genes have been identified.
SUBJECTS AND METHODS
Patients presentingwith episodes of ataxia that began before age 30
underwent interview, neurological examination, laboratory inves-
tigation, neuroimaging studies, and genetic screening. This study
was approved by the institutional review boards, and all sub-
jects or their guardians provided written consent. A subset of the
patients was also enrolled in the EA arm of the Consortium for the
Clinical Investigation of Neurological Channelopathies (CINCH)
study, a multicentered study sponsored by the Rare Diseases Clin-
ical Research Network supported by the National Institutes of
Health.
Therewere 47unrelated subjectswith onset of EAbefore the age
of 30 years in whomwe could not identifymutations in the known
EA1, EA2, and EA6 genes. Among these subjects, four exhib-
ited EA1-like features characterized by brief ataxia episodes with
interictal myokymia. Twenty-six subjects presented with EA2-like
features. One subject had EA6-like features, with episodic ataxia,
seizures, alternating hemiplegia beginning during infancy. There
were 16 subjects who experienced EA without interictal nystag-
mus or myokymia but had other eye movement abnormalities,
movement disorder, or sleep disturbance.
We searched for genomic rearrangement in CACNA1A in 47
EA patients without known mutations by multiplex ligation-
dependent probe amplification (MLPA; Schouten et al., 2002)
using Kit P279 (MRC-Holland) on an ABI 3730 DNA Analyzer
(Applied Biosystems) and processed the data by GeneMarker
(Softgenetics).
Mindful of Alu-mediated chromosomal recombination (Riant
et al., 2008, 2010; Cordaux and Batzer, 2009) and the high density
(30%)ofAlu sequences spanningCACNA1A,we identifiedAlu ele-
ments in CACNA1A by bioinformatic mining (genome.ucsc.edu)
and prioritized candidate Alu elements with high similarity by
pairwise alignment bl2seq (NCBI http://www.ncbi.nlm.nih.gov/).
The breakpoints were ascertained by sequencing.
To locate the breakpoints for the deletion in patient #946, we
performed long-range PCR based on the manufacturer’s protocol
(Takara Bio), with 10 forward primers between exon 1 and exon
4 and four reverse primers after exon 47. Primers were designed
∼10 kb apart as guided by the distribution of Alu elements, num-
bering more than 80 in the 134 kb candidate region for the 5′
breakpoint. Primer sequences are available on request. Long-range
PCR narrowed the candidate region, for which all Alu elements
were identified and aligned with those downstream of CACNA1A,
as analyzed by bl2seq (Table 1).
Genotyping. In Pt #444 and her father, we typed a series of
microsatellite markers on 19p flanking CACNA1A in addition to
other microsatellite markers on multiple chromosomes.
RESULTS
We observed a 50% reduction in the signal for multiple MLPA
probes (Figure 1) in threeunrelatedprobandswith classic EA2-like
features: episodes of prolonged vertigo and ataxia triggered by
stress and fatigue, interictal nystagmus, with onset during infancy
or early childhood (Table 2).
Patient #444 began suffering episodic imbalance and vertigo
at age 8 years. Vertigo was preceded by non-throbbing neck pain
and was accompanied and followed by nausea and repeated vom-
iting. She also noted blurred vision not corrected by refraction,
but denied oscillopsia or diplopia. Episodes occurred daily or
every other day and lasted two or more hours. She also experi-
enced severe motion sickness and frequent throbbing headaches
not temporally related to episodic dizziness. The patient was
noted to have nystagmus at the age of 6months. Developmen-
tal milestones were appropriate. Family history is positive for
migraine in her father and paternal grandmother. Physical exam-
ination showed impaired pursuit, downbeat nystagmus in pri-
mary gaze, and multidirectional gaze-evoked nystagmus, with
stiff and wide-based gait. Two MRIs were normal. The patient
has responded well to acetazolamide 250mg twice or three times
daily, with complete resolution of dizziness but not her headaches
(Figure 2).
Patient #946 presented at age 17months with recurrent attacks
of vertigo and ataxia associated with severe nausea and vomiting.
During the attacks, her balance is severely impaired with slurring
of speech such that she needs to lie down to sleep. The attacks
typically last for several hours, and they are triggered by exertion
or stress, or they can occur abruptly without any apparent cause.
Her development is delayed: walking at around 17months, and
speaking her first words around 3 years. She is in special educa-
tion. Family history is negative for similar symptoms of recurrent
vertigo and ataxia.Mother hasmigraine. Her examination showed
impaired pursuit, horizontal and downward gaze-evoked nystag-
mus, dysdiadochokinesis, and mild difficulty in tandem walking.
Routine blood work, EEG, auditory brainstem evoked responses,
and brain MRI were all normal. She had tried various differ-
ent medications including carbamazepine, periactin, meclizine,
and promethazine without improvement. She has not yet tried
acetazolamide (Figure 2).
Patient #2021 had the onset of episodic dizziness associated
with imbalance, nausea, occasional emesis, and tinnitus at the age
of 7 years. Episodes are triggered by exercise, stress, and anxiety,
persist for 20–120min, and are relieved by stopping activities, lying
down, or sleeping. The patient is active in sports, playing soccer,
and wrestling. Feeling “overheated” while participating in these
activities often triggers an event. During the episodes of dizziness,
he feels warm,has a sense of moving,his speech slurs, and his limbs
feel like “rubber” or “jello.” His past medical history is notable
for frequent ear infections, associated with a transient bilateral
hearing impairment and speech delay of approximately 6months.
Childhood development was otherwise normal, academically he
has done well through high school, and he has been treated for
depression. Family history is significant with his father having
a similar, but milder, condition that began in childhood and was
triggered by exercise.MRI andMRA studies in the father were nor-
mal. On physical examination, the patient had impaired smooth
pursuits, saccadic dysmetria, gaze-evoked nystagmus, but other-
wise steady gait and coordination. Treatment with acetazolamide
produced some benefit (Figure 2).
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FIGURE 1 | Newly identified and previously reported EA2-causing
genomic rearrangements in CACNA1A that vary in size and location.
In a diagram of the genomic structure of CACNA1A on chr 19 spanning
approximately 300, 000 base pairs (shaded in gray), the vertical bars
represent exons, and those in red harbor target sequences for the MLPA
probes. The locations of exons 1, 4, 38, and 47 are specified. The rectangles
highlighted in blue below the genomic structure of CACNA1A represent
missing MLPA probes in the patients, labeled with the sizes and deleted
exons. The open rectangles above the genomic structure of CACNA1A
represent previously described deletions, with established boundaries, in five
unrelated kindreds with EA2 (Riant et al., 2008, 2010), along with additional
instances of genomic rearrangements without breakpoint ascertainment by
Labrum et al., 2009; open circle – missing MLPA probe; closed circle –
duplicated MLPA probe.
Table 2 | Clinical features.
Clinical features Pt#444 Pt#946 Pt#2021
Age of symptom
onset, yrs
8 1.4 7
Age at diagnosis
of EA
15 10 13
Triggers Exertion/stress Exertion/stress Exertion/stress
Duration of attack Hours Hours Hours
Nystagmus All directions All directions All directions
Baseline ataxia Mild Mild None
Response to
acetazolamide
Good Unknown Good
Family history Negative Negative Father
Weconfirmedmulti-exonic deletions by ascertaining the break-
points (Figure 3). In Patient #444, the heterozygous deletion
spanned exons 39 through 47 (Figures 1 and 3) to predict a trun-
cated protein, if translated,missing theC-terminus (Figure 4).Her
father was not found to have this same deletion; and genotyping of
microsatellite markers on multiple chromosomes of Patient #444
and her father confirmed paternity. The genotyping results of 19p
markers (from5′ to 3′, 19S226,19S1150,polymorphicCAGrepeats
in exon 47, and 19S221) are shown with the pedigree. Specifically,
sequencing of the polymorphic CAG repeats in Patient #444 con-
firmed thedeletionof oneof the two alleles for exon47; the absence
of either paternal alleles of 11 and 13 repeats in the patient sug-
gests that the deletion occurred de novo on a paternal allele of
CACNA1A (Figure 2).
The largest deletion, missing all but the first three exons, was
found in Patient #946 (Figures 1 and 3). DNA samples from
her parents were not available for testing. The candidate region
of the 5′ breakpoint included sequences downstream of exon
1 and upstream of exon 4, which spanned 134 kb. Identifying
the most highly homologous Alu sequences in the candidate
regions facilitated the identification of the breakpoints (Table 1).
FIGURE 2 |The pedigrees for the probands, indicated by arrowheads.
(*, DNA sample obtained; closed symbol, affected; circle – female; square –
male). Genotyping of Patient #444 and her father with 19p markers (from 5′
to 3′, 19S226, 19S1150, polymorphic CAG repeats, and 19S221) are shown
with the pedigree. Haplotypes shared between the patient and the father
are highlighted by rectangles.
We confirmed the 200 kb deletion, for which the 5′ breakpoint
resided in an Alu sequence in intron 3 that harbored a long
stretch of identical sequences and shared high similarity (88%)
with the 3′ breakpoint in an Alu sequence 10 kb downstream of
CACNA1A (Table 1; Figure 3). If made, the predicted mutant
gene product constitutes only three transmembrane segments
(Figure 4).
The smallest deletion, spanning exons 39 and 40, was found in
Patient #2021 and subsequently his symptomatic father (Figures 1
and 3). This deletion is predicted to cause a shift in the open read-
ing frame to introduce 79 novel residues downstream of residue
1917 and a premature stop codon (Figure 4).
The breakpoints in all three probands involved Alu sequences:
AluY -AluY in #946; FLAM_C-AluSx in #444; and AluSq-AluJb in
#2021 (Figure 3). The Alu element pairs shared high similarity,
with a length of identical stretch of nucleotides ranging from 24
to 48 and an overall similarity of 76–88%.
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FIGURE 3 | Breakpoint ascertainment.The red lines highlight the stretch of
identical sequence shared by the 5′ and 3′ Alu elements that mediated
homologous recombination, with specific nucleotide positions for the 5′ and
for the 3′ Alu elements. The 3′ breakpoints downstream of the CACNA1A
gene are labeled based on the March 2006 human reference sequence (hg18,
NCBI Build 36.1).
DISCUSSION
We focused our genetic investigation on individuals with onset
of EA early in life. We identified novel large genomic dele-
tions in three unrelated subjects. All three deletions resulted
from homologous recombination of Alu elements, as previously
observed by Riant et al. (2008, 2010). The deletion in Pt #444 arose
de novo. Because the parents were asymptomatic, we suspected
that the deletion in Pt #946 likely also occurred spontaneously;
however, DNA samples from the parents were not available for
testing.
Riant et al. (2010) used the quantitative multiplex polymerase
chain reaction of short fluorescent fragments method to probe
every exon to identify large genomic deletions in 4 of 27 probands
with typical EA2-like features. Labrum et al. (2009) using MLPA
with partial but incomplete probes for CACNA1A identified
genomic duplication or deletion in 10 of 53 subjects with EA2
or its allelic disorder familial hemiplegic migraine. Of note, in five
of the subjects, the deletions involved the same exons 39–47; none
had a positive family history. We also used MLPA to identify new
deletions in 3 of 26 probands with EA2-like clinical features in a
cohort of 47 subjects with EA onset before age 30. In Pt #444, we
demonstrated that the genomic rearrangement involving the dele-
tion of exons 39–47 arose spontaneously from the paternal allele.
Whether genomic rearrangement of CACNA1A may contribute to
late-onset EA await further analysis.
The genomic rearrangements in CACNA1A described thus far
are highly variable in size and location (Figure 1; Riant et al.,
2008, 2010; Labrum et al., 2009). Given the high density of Alu
elements estimated to occupy approximately 30% of the genomic
sequence of CACNA1A, we expect many more instances of large
genomic rearrangements elsewhere in this gene. Our findings
further emphasize that genomic rearrangement is an important
www.frontiersin.org September 2011 | Volume 2 | Article 51 | 5
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FIGURE 4 | Predicted gene products of the mutated alleles, if
translated, in orange, superimposed on the wild type Cav2.1 (in gray)
spanning 2510 amino acid residues, with four homologous domains,
each with six transmembrane segments.The intracellular C-terminus is
largely missing in #444 (with truncation at residue 1917, arrow). The predicted
gene product of the mutated allele in Pt #946 encodes only the first three
transmembrane segments. The gene product in Pt#2021 of the mutated
allele with the deletion of exon 39–40, if translated, is predicted to comprise
79 novel residues (in green) following residue 1917, missing the tail
(gray).
cause of EA2 and should be included in the genetic analysis of
CACNA1A.
Our observations highlight challenges in the clinical diagnosis
and genetic definition of episodic ataxia. Perhaps because of its
rarity, EA is under-recognized and under-diagnosed. In each of
the three subjects described in this report, it took several years and
extensive clinical testing to reach the clinical diagnosis of episodic
ataxia, which was followed by another several years before the
genetic confirmation of EA2. There remain many patients with
EA2-like clinical features without mutations in the EA2 gene,
suggesting genetic heterogeneity although the possibility of unde-
tected intronic or promoter mutations in the CACNA1A gene still
exists.
While MLPA is relatively straightforward to perform and ana-
lyze, there was extensive random variation of single probe inten-
sity, especially for exon 47. The absence of Alu elements in
intron 46 suggests that the deletion of exon 47 alone may be
unlikely, as confirmed by sequencing of the polymorphic CAG
repeats in exon 47 in samples with low signal for exon 47 but
normal signal for exon 46. The distribution of Alu sequences
may be considered in developing additional MLPA probes for
CACNA1A.
Although there is general consensus that most of the muta-
tions that cause EA2 result in loss of calcium channel function, it
is not clear whether they cause disease by haploinsufficiency or a
dominant negative effect. Understanding the disease mechanism
may help guide treatment. Results from in vitro expression studies
suggested a dominant negative effect (Jouvenceau et al., 2001; Page
et al., 2004,2010; Jeng et al., 2006;Mezghrani et al., 2008).Yet, these
studies all used artificial cDNA constructs in heterologous cell
expression systems that bypass nonsense-mediated mRNA decay,
which is a stringent cellular mRNA surveillance mechanism that
detects and degrades mRNAs with nonsense mutations to pre-
vent the expression of truncated proteins. The recently described
frameshift mutation c.165dupA predicted to lead to only a frag-
ment of the N-terminal tail even if translated; this short peptide
does not contain any motif for interaction with the auxiliary sub-
units or the wild type Cav2.1, leading the investigators to favor
haploinsufficiency over a dominant negative effect (Mantuano
et al., 2010). Similarly, the deletion of over 200 kb in Pt #946 is
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unlikely to lead to a stable gene product to exert a dominant nega-
tive effect on the gene product of the normal allele. The finding of
genomic deletions of variable sizes in CACNA1A all causing simi-
lar clinical features suggests sharedmechanisms for these deletions
as null alleles through haploinsufficiency.
Genetic characterization of EA2 not only is important for diag-
nosis but alsomay dictate the choice of treatment.New therapeutic
strategies are being developed to intervene at the level of splicing
(Wilton et al., 2007), translation (Welch et al., 2007), and post-
translational quality control (Williams et al., 2006) to restore the
function of nonsense, splice site, or missense mutants. On the
other hand, those patients with large genomic rearrangements
in EA2 will likely benefit the most from medications with tar-
gets downstream from the mutant calcium channels to restore
cerebellar neuronal function. Our patients have demonstrated
modest responses to acetazolamide, which is a carbonic anhydrase
inhibitor with no direct influence on calcium channels, and whose
efficacy in EA and other neurological channelopathies has not
been elucidated (Griggs et al., 1978). Recently, 4-aminopyridine, a
voltage-gatedpotassiumchannel blocker,has emerged as a promis-
ing alternative to acetazolamide. 4-aminopyridine was found to be
effective in stopping attacks in patientswithEA (Strupp et al., 2004,
2011) as well asmutantmice (Weisz et al., 2005), likely by restoring
the precision of cerebellar Purkinje cell pacemaking (Alvina and
Khodakhah, 2010). An FDA-sponsored randomized trial is now
underway on the efficacy and tolerability of 4-aminopyridine in
EA2.
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Neurology, UK), Angelika Hahn (London Health Science Cen-
tre, Canada), Michael G. Hanna (Institute of Neurology, UK),
Kim Hart (University of Rochester), Laura Herbelin (University
of Kansas), Barbara Herr (University of Rochester), Yunxia Wang
(University of Kansas).
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